Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) announced that Paul Bolno, MD, MBA, President and CEO, will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the company's Investor Events page and a replay will be archived for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – WVE
In the Feb 23 session, WVE gained 0.07%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings call scheduled | Neutral | +0.9% | Announced date and webcast details for Q4 and full-year 2025 results. |
| Feb 02 | Regulatory strategy update | Positive | +3.8% | Regained WVE-006 rights, outlined accelerated regulatory plans and milestone potential. |
| Jan 12 | Pipeline priorities update | Positive | +0.5% | Detailed 2026 priorities for obesity candidate and RNA editing portfolio with cash runway. |
| Jan 05 | Conference presentation | Neutral | -6.0% | Notified investors of J.P. Morgan conference presentation and webcast access. |
| Dec 09 | Equity offering priced | Negative | +15.1% | Priced upsized public offering of ordinary shares and pre-funded warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Substantive pipeline and strategic updates have coincided with positive moves, while event-only announcements and financing have shown mixed or divergent reactions.
Over the last few months, Wave Life Sciences issued several notable updates. On Feb 2, 2026, it announced accelerated regulatory plans and expanded collaboration economics, with a +3.79% move. Strategic priorities for 2026 on Jan 12, 2026 were followed by a modest +0.51% reaction. By contrast, a simple conference appearance notice on Jan 5, 2026 saw a -5.96% move, and the $350M offering on Dec 9, 2025 coincided with a +15.06% gain, highlighting non-linear reactions to financing and event news.
Key Terms
rna medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
